8-K: Surrozen Pivots to Ophthalmology, Reports Q1 2025 Financial Results

Surrozen announced its Q1 2025 financial results, highlighting a strategic shift to ophthalmology and discontinuing its SZN-043 program.

Summary

• Surrozen reported its financial results for the first quarter ended March 31, 2025.
• The company is now focusing on its ophthalmology pipeline, including SZN-8141 and SZN-8143, and has discontinued development of SZN-043.
• Surrozen expects to file an Investigational New Drug (IND) application for SZN-8141 in 2026.
• FDA clearance of the IND application would trigger funding of a $98.6 million private placement tranche.
• Cash and cash equivalents were $101.6 million as of March 31, 2025, compared to $34.6 million as of December 31, 2024.
• This increase was due to $76.4 million in gross proceeds from the first closing of a $175 million private placement in March 2025.
• Research service revenue from a related party was $1.0 million for the quarter.
• Research and Development expenses were $6.6 million, compared to $5.2 million for the same period in 2024.
• General and Administrative expenses were $4.0 million, comparable to $3.9 million for the same period in 2024.
• Net loss was $27.0 million, or ($7.43) per share, compared to a net loss of $8.8 million, or ($4.24) per share, for the same period in 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has a strong cash position and a clear strategic focus, the increased net loss and discontinuation of a program are concerning.

Positives

• The strategic pivot to ophthalmology is supported by a recent $175 million financing.
• Cash position significantly improved to $101.6 million due to private placement proceeds.
• Collaboration with Boehringer Ingelheim continues on SZN-413 for retinal vascular-associated diseases.
• Research service revenue from a related party increased to $1.0 million.

Negatives

• Discontinuation of SZN-043 program indicates a setback in the company's initial development plans.
• The company reported a net loss of $27.0 million, significantly higher than the $8.8 million loss in the same period last year.
• Loss on execution of the 2025 PIPE was $71.1 million, reflecting the non-cash loss recognized upon the execution of the private placement.

Risks

• The success of the ophthalmology pipeline is dependent on successful clinical trials and regulatory approvals.
• The company's ability to fund its preclinical and clinical trials depends on existing funds or additional fundraising.
• Volatility in global economic, political, regulatory, and market conditions could impact the company's operations and financial results.
• There is a risk that the IND application for SZN-8141 may not be cleared by the FDA.

Future Outlook

Surrozen anticipates filing an IND application for SZN-8141 in 2026 and expects the second private placement tranche to fund operations through efficacy, safety, and tolerability studies for SZN-8141 and SZN-8143.

Management Comments

• Craig Parker, President and Chief Executive Officer of Surrozen, stated that the company is thrilled about the opportunity to advance its novel ophthalmology pipeline.
• He also mentioned that the strategic pivot to ophthalmology, supported by the recent $175 million financing, positions the company to deliver innovative therapies.

Industry Context

Surrozen's focus on ophthalmology and Wnt pathway modulation aligns with growing interest in novel treatments for severe eye diseases like AMD and diabetic retinopathy, where unmet needs remain despite existing anti-VEGF therapies. The company's approach of combining Fzd4 agonism with VEGF antagonism and IL-6 antagonism could offer a differentiated therapeutic strategy.

Comparison to Industry Standards

• Surrozen's approach of combining Fzd4 agonism with VEGF antagonism is similar to other companies exploring multi-targeted therapies for retinal diseases.
• Regeneron's Eylea is a leading anti-VEGF therapy for wet AMD and DME, and Surrozen aims to differentiate its candidates by targeting the Wnt pathway in addition to VEGF.
• Companies like Roche and Novartis are also developing novel therapies for retinal diseases, including gene therapies and bispecific antibodies.
• Surrozen's collaboration with Boehringer Ingelheim on SZN-413 is similar to other partnerships in the biotechnology industry, where larger companies collaborate with smaller companies to develop novel therapies.

Related Party Transactions

• Research service revenue from a related party was $1.0 million for the quarter, driven by the collaboration with TCGFB, Inc.

Stakeholder Impact

• Shareholders: The strategic shift to ophthalmology and the private placement may impact shareholder value.
• Employees: The discontinuation of SZN-043 may affect employees working on that program.
• Patients: The development of new ophthalmology treatments could benefit patients with severe eye diseases.

Next Steps

• File an Investigational New Drug (IND) application with the FDA for SZN-8141 in 2026.
• Advance SZN-8141 and SZN-8143 toward clinical studies.
• Continue collaboration with Boehringer Ingelheim on SZN-413.

Key Dates

Keywords

ophthalmology, SZN-8141, SZN-8143, Wnt pathway, retinal diseases, financial results, Surrozen, biotechnology